Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era
10.19401/j.cnki.1007-3639.2025.03.003
- VernacularTitle:CDK4/6抑制剂后时代下的乳腺癌精准诊疗
- Author:
Bin LI
1
;
Zhonghua TAO
;
Xichun HU
Author Information
1. 复旦大学附属肿瘤医院肿瘤内科,复旦大学上海医学院肿瘤学系,上海 200032
- Publication Type:Journal Article
- Keywords:
Hormone receptor-positive advanced breast cancer;
Cyclin-dependent kinase 4 and 6 inhibitor;
Precision medicine;
Endocrine therapy;
Targeted therapy;
Antibody-drug conjugate
- From:
China Oncology
2025;35(3):273-282
- CountryChina
- Language:Chinese
-
Abstract:
Cyclin-dependent kinase(CDK)4/6 inhibitors plus endocrine therapy represents the standard first-line treatment for patients with hormone receptor-positive,human epidermal growth factor receptor 2(HER2)-negative advanced breast cancer.The introduction of CDK4/6 inhibitors has significantly improved the prognosis of breast cancer patients.However,it has also brought new clinical challenges,such as disease progression and treatment resistance in many patients.Currently,there is a lack of standardized subsequent treatment options for patients whose disease progresses after CDK4/6 inhibitor combined with endocrine therapy.Endocrine therapy resistance can lead to tumor progression through estrogen receptor(ESR)-dependent or ESR-independent pathways.Novel endocrine agents have the potential to benefit breast cancer patients harboring ESR1 mutations.Patients with alterations in the phosphoinositide 3-kinase(PI3K)/protein kinase B(AKT)/mammalian target of rapamycin(mTOR)pathway may be particularly sensitive to targeted inhibitors of this pathway.Furthermore,newly approved or investigational antibody-drug conjugate(ADC),immunotherapy-based combinations,and novel cell cycle inhibitors have demonstrated promising anti-tumor activities.Precision medicine-based combination strategies not only expand clinical treatment options but also enable physicians to make personalized treatment decisions for patients.Biomarker-driven precision therapeutic strategies have emerged as a critical area of treatment development in the post-CDK4/6 inhibitor era.
